Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

European Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2001, Pages 123-127

  Bergmann, T ^a   Bathum, L ^b   Brosen, K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CYP2D6; Desipramine; Gene duplication; Rapid metabolism

Indexed keywords

CYTOCHROME P450 2D6; DESIPRAMINE; SPARTEINE; SPARTEINE SULFATE;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DENMARK; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENE DUPLICATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DENMARK; DESIPRAMINE; FEMALE; GENE DUPLICATION; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OXYTOCICS; PREDICTIVE VALUE OF TESTS; SPARTEINE;

EID: 0035031859     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100284     Document Type: Article

References (22)

1. 1.Hammer W, Sjöqvist F (1967) Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 6:1895-1903
2. 2. Bertilsson L, Aberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 15:388-390
3. 3. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
4. 4. Heim M, Meyer UA (1991) Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 206:173-183
5. 5. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L (1986) Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30:679-684
6. 6. Brosen K, Otton SV, Gram LF (1986) Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40:543-549
7. 7. Mellstrom B, Bertilsson L, Lou YC, Sawe J, Sjöqvist F (1983) Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 34:516-520
8. 8. Bertilsson L, Dahl ML, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist F, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:363
9. 9. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
10. 10. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446
11. 11. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
12. 12. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520
13. 13. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brosen K (1998) Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 8:119-123
14. 14. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P4502D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
15. 15. Agundez JA, Ledesma MC, Ladero JM, Benitez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265-269
16. 16. Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Horder M, Brosen K (1999) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395-401
17. 17. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444-452
18. 18. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellstrom B, Steiner E, Sjöqvist F (1984) Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 36:677-682
19. 19. Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 31:23-29
20. 20. Nielsen KK, Brosen K (1993) High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. J Chromatogr 612:87-94
21. 21. Gardner MJ, Altman DG, Campbell MJ (1989) Statistics with confidence. Confidence intervals and statistical guidelines. Br Med J, London
22. 22. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349-355